Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticariaMarcus Maurer, Julian Storim, Adam Reich et al.|Journal of Allergy and Clinical Immunology|2022Cited by 158